Abstract: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

Abstract: The present invention relates to a skin-moisturizing or wrinkle-improving external composition or cosmetic composition which contains, as an active ingredient, a compound represented by Formula 1, which can be extracted from Anemarrhena asphodeloides Bunge, or a pharmaceutically acceptable salt thereof. The composition prevents skin moisture loss and thus suppresses skin tissue damage induced by UV rays and so has a skin-wrinkle preventing or alleviating effect.

Abstract: It has been determined that co-administration of a rifamycin and a switch-region inhibitor 1) results in synergistic antibacterial effects, enabling efficacy at low, subtoxic doses, and/or 2) results in a low spontaneous resistance frequency, enabling treatment of high-titer infections without treatment failure due to spontaneous resistance. Accordingly, certain embodiments provide a composition comprising a rifamycin and a switch region inhibitor, as well as methods of use thereof.

Abstract: The invention relates to the cosmetic use of at least one compounds according to the following formula (I), as an anti-dandruff agent or for preventing and/or treating scalp dandruff: where “sugar” denotes a monosaccharide residue chosen from rhamnose, xylose, fucose, mannose, lyxose, and arabinose; where R, substituting the anomeric oxygen in the sugar (represented by “O” in formula (I)), denotes a radical comprising 6 to 38 carbon atoms chosen from: —a linear or branched, saturated alkyl radical; —a linear or branched, alkenyl radical; said linear or branched saturated alkyl radical being optionally substituted by at least one OH and/or NH2 function; —if “sugar” denotes a mannose residue, R denotes a linear C6-C38 alkyl radical, substituted by at least one OH function or an NH2 function; and the salts and solvates and/or optical isomers thereof, alone or in a mixture, particularly racemic forms. The invention also relates to compounds according to formula (I), and cosmetic compositions containing same.

Abstract: The invention described herein pertains to a novel macrolide antibacterial agent of formula (I): A-L-Q, as defined herein, and pharmaceutically acceptable salts, solvates, and hydrates thereof. Inter alia, the new macrolide antibacterial agent is active against a number of bacterial species, including resistant species.

Abstract: A surfactant produced by reacting naturally occurring polysaccharides that are not water soluble with a hydrophilic substituent on a carboxylic portion of the polysaccharide. In a second reaction, the surfactant is further substituted on a hydroxylic portion with a hydrophobic or lipophilic substituent, so as to make the reaction product both water soluble and capable of attracting oily material that is hydrophobic to be removed from a substrate by cleaning in water. Methods of making the surfactant and the follow-on reaction product are described.

Abstract: A process for the crystallisation of a water-soluble compound is disclosed. The process comprises (a) providing, in a crystallisation vessel, a solution of the water-soluble compound in a mixture of water and a solvent in which the water-soluble compound has a lower solubility than in water; (b) passing vapor phase of the mixture through a sorption zone containing a water vapor sorbent to selectively adsorb water from the vapor phase; (c) recycling a part of the vapor phase to the crystallisation vessel or withdrawing vapor phase depleted in water from the process and adding solvent to the crystallisation vessel; (d) allowing solid crystals of the water-soluble compound to precipitate from the solution; and (e) discharging precipitated solid crystals of the water-soluble compound from the crystallisation vessel and discharging a solution of non-crystallised water-soluble compound in water-solvent mixture from the crystallisation vessel.

Abstract: The present invention relates to the field of medicinal chemistry, and discloses a new crystal form of regadenoson, i.e., a crystal form E of regadenoson, as well as a method for preparing the new crystal form of regadenoson. The crystal form E of regadenoson according to the present invention has excellent performances in terms of radionuclide myocardial perfusion imaging, and has a poor toxicity, good storage stability, and can be used in the preparation of a medicament used as a stress agent for radionuclide myocardial perfusion imaging.

Abstract: Cells incorporating a synthetic molecule construct of the structure F—S1—S2-L where: F—S1 is an aminoalkylglycoside where F is a mono-, di-, tri- or oligo-saccharide and S1 is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl; S2 is —CO(CH2)2CO—, —CO(CH2)3CO—, —CO(CH2)4CO— or —CO(CH2)5CO—; and L is phosphatidylethanolamine.

Abstract: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.

Abstract: The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.

Abstract: Hyper-branched maltodextrins having a dextrose equivalent (DE) between at least 8 and at most 15 and a molecular weight or Mw between at least 1,700 and at most 3,000 daltons, characterized in that same have: a 1,6 glucoside bond content between at least 30 and at most 45%; a soluble indigestible fiber content, which is determined according to the AOAC No. 2001-03 method, between at least 75 and at most 100%; and a hypoglycemic capacity expressed according to a test A, which:—in vitro, results in an 80 to 90% reduction of the ?-amylase hydrolysis of standard maltodextrins, and—in situ, by a 30 to 45% reduction in the intestinal digestive activity of standard maltodextrins.

Abstract: The present invention relates to a method for crosslinking hyaluronic acid, a method for preparing an injectable hydrogel, the hydrogel thus obtained and its use.

Abstract: The present invention includes a composition comprising an effective amount of an avermectin compound, and an effective amount of an imidazole antifungal compound, and/or an effective amount of non-steroidal anti-inflammatory drug (NSAID) or suitable pharmaceutically acceptable salts thereof, for use in the inhibition of tumor growth and treating urothelial, colorectal, prostate and/or breast cancers. Furthermore, the invention includes a method of inhibiting tumor growth and treating said cancers comprising administering to a subject in need thereof an effective amount of said composition.

Abstract: The present invention is directed to 4?-substituted nucleoside derivatives of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC.

Abstract: The invention concerns compounds of the formula (I) wherein: Y1 and Y2 are independently a monosaccharide or disaccharide; X1 and X2 are independently —(R9—O)m—, —(R10)p—, —O—(R11—O)q—, —R16—O—R17—O— or a covalent bond; Q1 and Q2 are independently a nitrogen-containing heterocycle moiety; Z1 and Z2 are independently —(O—R7)—, —(O—C(?O)—R8)a-, —O—C(?O)—R12—C(=0)-R13—, —O—C(?O)—R14—C(?O)—R15 or a covalent bond; R7-R17 are each independently C1-C6 alkyl; R1-R6 are each independently a linear or branched alkyl group; b, c, d, e, f, and g are 0 or 1, provided b+c+d equals at least 2 and e+f+g equals at least 2; and a, m, p, and q are each an integer from 1-6.

Abstract: The invention relates to novel saccharides and uses thereof. In one aspect, the invention relates to a saccharide having a legionaminic acid moiety, a N-acetylgalactosamine moiety, a galactose moiety, and a glucose moiety. In another aspect, the invention relates to a saccharide having an altruronic acid moiety, a fucose moiety, and a glucose moiety. In yet another aspect, the invention relates to a saccharide having a repeating unit of a glycerol phosphate moiety and a glucose moiety, wherein the saccharide is from Enterococcus faecium. In a further aspect, the invention relates to a saccharide having a repeating unit of -6-?-D-Fruf-2, wherein Fru is a fructose moiety, wherein the saccharide is from Enterococcus faecium. In another aspect, the invention relates to an isolated antibody or fragment thereof that specifically binds to a saccharide described herein and uses thereof.

Abstract: The present invention relates to new macrolide derivatives, in particular new tylosin derivatives of the formula (IIa), a pharmaceutical or veterinary composition comprising the derivatives; a method for preparation thereof; a method for treating and/or preventing bacterial infections in an animal, wherein the method comprises administering the derivatives or the composition; and a use of the derivatives for the manufacture of medicaments for treating and/or preventing bacterial infections in an animal.

Abstract: The present invention relates to a Rehmannia glutinasa Libosch. extract for reducing blood glucose and lipid levels and treating hematologic diseases such as leukemia, and methods for preparing the same. The extract is prepared by subjecting fresh Rehmannia glutinasa Libosch. to flux extraction, concentrating the resultant extract, dissolving the concentrated extract with water, loading the obtained solution on a column packed with macroporous adsorption resins, eluting the column with ethanol, concentrating and drying the eluate. The extract can be made into clinically acceptable forms of dosage by pharmaceutically conventional measures, including capsule, tablet, pill, granule, dropping pill and so on. The extract is stable and has catalpol content up to 90-98%. The preparing method is simple to operate and applicable to industrial-scale production.

Abstract: An alkenyl glycoside is prepared by reacting a metathesis-derived unsaturated fatty alcohol containing 10 to 30 carbon atoms with either (1) a reducible monosaccharide or composition hydrolyzable to a reducible monosaccharide, or (2) a hydrocarbyl glycoside produced by reacting an alcohol containing up to 6 carbon atoms with a reducible monosaccharide or composition hydrolyzable to a reducible monosaccharide. Each of these reactions is performed in the presence of an acid catalyst and under conditions sufficient to form the alkenyl glycoside or hydrocarbyl glycoside. The preferred alkenyl glycosides are 9-decen-1-yl glycoside; 9-dodecen-1-yl glycoside; 9-tridecen-1-yl glycoside; 9-pentadecen-1-yl glycoside; 9-octadecen-yl glycoside; or 9-octadecen-1,18-diyl glycoside.